Jordy Schaukens

Laarbeeklaan 103
1090 Jette
Belgium
Laarbeeklaan 101
1090 Brussels
Belgium
Pleinlaan 2
1050 Brussel
Belgium

Research activity per year

Fingerprint

Dive into the research topics where Jordy Schaukens is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

1 Finished

ANI330: Preclinical development of a T cell product tunable by soluble factors for melanoma and glioblastoma patients refractory to prior intratumoral immunotherapy.
Tuyaerts, S. & Schaukens, J.
1/12/22 → 30/11/23
Project: Fundamental

5 Poster

Activation of PD-1K78A CAR transduced T-cells via clinical grade anti-PD-1 monoclonal antibodies
Schaukens, J., De Vlaeminck, Y., Geeraerts, X., Stevens, L., Breckpot, K., Neyns, B. & Tuyaerts, S., 15 May 2024.
Research output: Unpublished contribution to conference › Poster
Development of a PD-1K78A CAR selectively activated by clinical grade anti-PD-1 monoclonal antibodies.
Schaukens, J., De Vlaeminck, Y., Geeraerts, X., Stevens, L., Breckpot, K., Neyns, B. & Tuyaerts, S., 18 Apr 2024.
Research output: Unpublished contribution to conference › Poster
Decipher novel cytotoxic T cell resistant mechanisms in lung cancer
Benoot, T., Goyvaerts, C., Breckpot, K., De Ridder, K., Calderon Espinosa, E. S. & Schaukens, J., 2023, (Unpublished).
Research output: Unpublished contribution to conference › Poster
Decipher novel cytotoxic T-cell resistant mechanisms in lung cancer
Benoot, T., Goyvaerts, C., Breckpot, K., De Ridder, K., Calderon Espinosa, E. S. & Schaukens, J., 2023, (Unpublished).
Research output: Unpublished contribution to conference › Poster
Validation of anti-PD-1 monocolonal antibody binding to novel Immune checkpoint based Chimeric Antigen Receptors for better anti-tumor activity in glioblastoma patients.
Schaukens, J., De Vlaeminck, Y., Geeraerts, X., Stevens, L., Breckpot, K., Neyns, B. & Tuyaerts, S., 27 Oct 2023.
Research output: Unpublished contribution to conference › Poster

File
13 Downloads (Pure)

1 CERL: Community Engaged Research and Learning activities

Dag van de wetenschap
Jordy Schaukens (Participant)
27 Nov 2022
Activity: Other › CERL: Community Engaged Research and Learning activities

Creation of a 3D Crime scene to unravel cytotoxicity resistance mechanisms in non-small cell lung cancer
Author: Schaukens, J., Goyvaerts, C., Breckpot, K. & De Ridder, K., Jul 2022
Student thesis: Master's Thesis

Jordy Schaukens

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

ANI330: Preclinical development of a T cell product tunable by soluble factors for melanoma and glioblastoma patients refractory to prior intratumoral immunotherapy.

Activation of PD-1K78A CAR transduced T-cells via clinical grade anti-PD-1 monoclonal antibodies

Development of a PD-1K78A CAR selectively activated by clinical grade anti-PD-1 monoclonal antibodies.

Decipher novel cytotoxic T cell resistant mechanisms in lung cancer

Decipher novel cytotoxic T-cell resistant mechanisms in lung cancer

Validation of anti-PD-1 monocolonal antibody binding to novel Immune checkpoint based Chimeric Antigen Receptors for better anti-tumor activity in glioblastoma patients.

Dag van de wetenschap

Creation of a 3D Crime scene to unravel cytotoxicity resistance mechanisms in non-small cell lung cancer

Jordy Schaukens

Fingerprint

Collaborations and top research areas from the last five years

Projects

Research output

Activities

Thesis